{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:49Z","timestamp":1793835889389,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,11,9]]},"DOI":"10.1038\/s41416-021-01547-y","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T18:12:43Z","timestamp":1632939163000},"page":"1365-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of CDK4\/6 inhibitors in preclinical models of malignant pleural mesothelioma"],"prefix":"10.1038","volume":"125","author":[{"given":"Elisabet","family":"Aliagas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Alay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mart\u00ednez-Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hern\u00e1ndez-Madrigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Gausachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-5388","authenticated-orcid":false,"given":"Maria","family":"Saig\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Busacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel J.","family":"Sharkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Palmero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C.","family":"Ruffinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Padrones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Llatj\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5727-2099","authenticated-orcid":false,"given":"August","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Dorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"S\u00e1nchez-C\u00e9spedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mu\u00f1oz-Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-3325","authenticated-orcid":false,"given":"Xavi","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/BLT.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716\u201324, 24A\u201324C.","journal-title":"Bull World Health Organ"},{"key":"1547_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaoncol.2019.0446","volume":"5","author":"T Chen","year":"2019","unstructured":"Chen T, Sun XM, Wu L. High time for complete ban on asbestos use in developing countries. JAMA Oncol. 2019;5:779\u201380.","journal-title":"JAMA Oncol"},{"key":"1547_CR3","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"R Hassan","year":"2019","unstructured":"Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116:9008\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1547_CR4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36:2863\u201371.","journal-title":"J Clin Oncol"},{"key":"1547_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135.","journal-title":"Nat Genet"},{"key":"1547_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jtho.2019.12.111","volume":"15","author":"R Guo","year":"2020","unstructured":"Guo R, DuBoff M, Jayakumaran G, Kris MG, Ladanyi M, Robson ME, et al. Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas. J Thorac Oncol. 2020;15:655\u201360.","journal-title":"J Thorac Oncol"},{"key":"1547_CR7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.jtho.2019.07.002","volume":"14","author":"MG Zauderer","year":"2019","unstructured":"Zauderer MG, Jayakumaran G, DuBoff M, Zhang L, Francis JH, Abramson DH, et al. Prevalence and preliminary validation of screening criteria to identify carriers of germline BAP1 mutations. J Thorac Oncol. 2019;14:1989\u201394.","journal-title":"J Thorac Oncol"},{"key":"1547_CR8","doi-asserted-by":"publisher","first-page":"e000266","DOI":"10.1136\/bmjresp-2017-000266","volume":"5","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5:e000266.","journal-title":"BMJ Open Respir Res"},{"key":"1547_CR9","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"1547_CR10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"1547_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","volume":"31","author":"S Popat","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O\u2019Brien M, Pope A, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31:1734\u201345.","journal-title":"Ann Oncol"},{"key":"1547_CR12","unstructured":"Fennel DO, Ottensmeier C, Califano R, Hanna GG, Ewings S, Hill K, et al. Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from the CONFIRM phase 3 trial. In: Presented at: International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer_Abstract PS01.11. 2020."},{"key":"1547_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"1547_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"1547_CR15","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365.","journal-title":"Cancer Discov"},{"key":"1547_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bjc.1997.91","volume":"75","author":"AM Bj\u00f6rkqvist","year":"1997","unstructured":"Bj\u00f6rkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer. 1997;75:523\u20137.","journal-title":"Br J Cancer"},{"key":"1547_CR17","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","volume":"66","author":"F L\u00f3pez-R\u00edos","year":"2006","unstructured":"L\u00f3pez-R\u00edos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970\u20139.","journal-title":"Cancer Res"},{"key":"1547_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","volume":"453","author":"S Dacic","year":"2008","unstructured":"Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, et al. Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627\u201335.","journal-title":"Virchows Arch"},{"key":"1547_CR19","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","volume":"11","author":"M Hylebos","year":"2016","unstructured":"Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol. 2016;11:1615\u201326.","journal-title":"J Thorac Oncol"},{"key":"1547_CR20","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1038\/sj.onc.1201870","volume":"16","author":"SP Frizelle","year":"1998","unstructured":"Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene. 1998;16:3087\u201395.","journal-title":"Oncogene"},{"key":"1547_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","volume":"583","author":"G Middleton","year":"2020","unstructured":"Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020;583:807\u201312.","journal-title":"Nature"},{"key":"1547_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6:353\u201367.","journal-title":"Cancer Discov"},{"key":"1547_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25\u201335.","journal-title":"Lancet Oncol"},{"key":"1547_CR24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl J Med. 2015;373:1672\u20133.","journal-title":"N. Engl J Med"},{"key":"1547_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jcb.240630504","volume":"24","author":"HK Oie","year":"1996","unstructured":"Oie HK, Russell EK, Carney DN, Gazdar AF. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl. 1996;24:24\u201331.","journal-title":"J Cell Biochem Suppl"},{"key":"1547_CR26","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.1158\/1078-0432.CCR-13-0736","volume":"19","author":"E Nadal","year":"2013","unstructured":"Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A. Epigenetic inactivation of microRNA-34b\/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013;19:6842\u201352.","journal-title":"Clin Cancer Res"},{"key":"1547_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","volume":"66","author":"J Bollard","year":"2017","unstructured":"Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, et al. Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017;66:1286\u201396.","journal-title":"Gut"},{"key":"1547_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-1-4939-8769-6_12","volume":"1862","author":"F P\u00fcschel","year":"2019","unstructured":"P\u00fcschel F, Mu\u00f1oz-Pinedo C. Measuring the activation of cell death pathways upon inhibition of metabolism. Methods Mol Biol. 2019;1862:163\u201372.","journal-title":"Methods Mol Biol"},{"key":"1547_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neo.2017.05.003","volume":"19","author":"MA Bonelli","year":"2017","unstructured":"Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A. et al. Combined inhibition of CDK4\/6 and PI3K\/AKT\/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 2017;19:637\u201348.","journal-title":"Neoplasia"},{"key":"1547_CR30","unstructured":"Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020."},{"key":"1547_CR31","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1158\/0008-5472.CAN-14-1606","volume":"74","author":"C Ambrogio","year":"2014","unstructured":"Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, et al. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res. 2014;74:5978\u201388.","journal-title":"Cancer Res"},{"key":"1547_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrm2233","volume":"8","author":"J Campisi","year":"2007","unstructured":"Campisi J, d\u2019Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729\u201340.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1547_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.","journal-title":"Breast Cancer Res"},{"key":"1547_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471\u20135.","journal-title":"Nature"},{"key":"1547_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.09.012","volume":"38","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero B, Alvarez-Fern\u00e1ndez M, Zapatero-Solana E, El Bakkali A, Men\u00e9ndez MDC, L\u00f3pez-Casas PP, et al. CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;38:584.","journal-title":"Cancer Cell"},{"key":"1547_CR36","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362:1416\u201322.","journal-title":"Science"},{"key":"1547_CR37","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","volume":"39","author":"V Wagner","year":"2020","unstructured":"Wagner V, Gil J. Senescence as a therapeutically relevant response to CDK4\/6 inhibitors. Oncogene. 2020;39:5165\u201376.","journal-title":"Oncogene"},{"key":"1547_CR38","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1101\/gad.219899.113","volume":"27","author":"M Bezzi","year":"2013","unstructured":"Bezzi M, Teo SX, Muller J, Mok WC, Sahu SK, Vardy LA, et al. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 2013;27:1903\u201316.","journal-title":"Genes Dev"},{"key":"1547_CR39","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1073\/pnas.1901323116","volume":"116","author":"S AbuHammad","year":"2019","unstructured":"AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma. Proc Natl Acad Sci USA. 2019;116:17990\u20138000.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1547_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/carcin\/bgq026","volume":"31","author":"E Varin","year":"2010","unstructured":"Varin E, Denoyelle C, Brotin E, Meryet-Figui\u00e8re M, Giffard F, Abeilard E, et al. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis. 2010;31:984\u201393.","journal-title":"Carcinogenesis"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01547-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01547-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01547-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:04:14Z","timestamp":1636416254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01547-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,11,9]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01547-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"18 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EN received research support from Roche, Pfizer, Bristol Myers Squibb and Merck Serono and participated in advisory boards from Bristol Myers Squibb, Merck Serono, Merck Sharpe & Dohme, Lilly, Roche, Pfizer, Takeda, Boehringer Ingelheim, Bayer, Amgen and Astra Zeneca. RP has participated in advisory boards from Bristol Myers Squibb, Merck Sharpe & Dohme, Roche, Pfizer, Lilly, Boehringer Ingelheim and Astra Zeneca. DF has received research support from Astex Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Merck Sharpe & Dohme, Lilly Oncology, Roche and participated in advisory boards from Atara Therapeutics, Bayer, Boehringer Ingelheim and Inventiva. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The retrospective cohort was approved by a National Ethical Committee, under the references 4\/LO\/1527 (a translational research platform entitled <i>Predicting Drug and Radiation Sensitivity in Thoracic Cancers\u2014also approved by University Hospitals of Leicester NHS Trust under the reference IRAS131283<\/i>) and 14\/EM\/1159 (retrospective cohort). Pleural effusions samples were obtained after patients signed the informed consent approved by the Hospital de Bellvitge Ethical Committee (PR152\/14). All the animal experiments were performed in accordance with protocols approved by Animal Research Ethics Committee at IDIBELL. This study was performed in accordance with the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}